Ratings by H.C. Wainwright (Matthew Keller)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/30/2026 | Iterum Therapeutics | ITRM | Downgrade | Neutral (Buy) |
0.04 (0.03) |
-25% | Details | |
| 3/2/2026 | Gyre Therapeutics | GYRE | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Sensei Biotherapeutics | SNSE | Downgrade | Neutral (Buy) |
9.38 (15.85) |
68.98% | Details | |
| 10/16/2025 | Gyre Therapeutics | GYRE | Maintain | Buy (Buy) |
|
Details | ||
| 9/2/2025 | Inflarx NV | IFRX | New Coverage | Buy (Buy) |
1.60 (2.06) |
28.75% | Details | |
| 8/26/2025 | Gyre Therapeutics | GYRE | New Coverage | Buy (N/A) |
8.20 (5.69) |
-30.61% | Details | |
| 8/5/2025 | Sensei Biotherapeutics | SNSE | Maintain | Buy (N/A) |
|
Details | ||
| 7/2/2025 | GRI Bio, Inc. | GRI | Maintain | Buy (Buy) |
|
Details | ||
| 6/26/2025 | Phio Pharma | PHIO | Maintain | Buy (Buy) |
|
Details | ||
| 6/17/2025 | Galectin Therapeutics | GALT | New Coverage | Buy (N/A) |
1.49 (2.35) |
57.72% | Details | |
| 6/11/2025 | GRI Bio, Inc. | GRI | Maintain | Buy (Buy) |
|
Details | ||
| 6/5/2025 | Phio Pharma | PHIO | New Coverage | Buy (N/A) |
2.10 (1.11) |
-47.14% | Details | |
| 6/2/2025 | Sensei Biotherapeutics | SNSE | New Coverage | Buy (N/A) |
0.30 (9.38) |
3026.67% | Details | |
| 5/8/2025 | Iterum Therapeutics | ITRM | New Coverage | Buy (N/A) |
0.92 (0.04) |
-95.65% | Details | |
| 4/14/2025 | GRI Bio, Inc. | GRI | Maintain | Buy (Buy) |
|
Details | ||
| 12/9/2024 | GRI Bio, Inc. | GRI | New Coverage | Buy (N/A) |
0.79 (2.01) |
154.43% | Details |
